-
公开(公告)号：US20220010000A1
公开(公告)日：2022-01-13
申请号：US17480984
申请日：2021-09-21
Applicant: BIOVERATIV THERAPEUTICS INC.
Inventor： Robert T. PETERS , Adam R. MEZO , Daniel S. RIVERA , Alan J. BITONTI , Susan C. LOW
IPC: C07K14/755 , C07K14/475 , C07K14/505 , C07K14/555 , C07K14/56 , C07K14/745 , C07K16/00 , C12N9/64 , A61K47/68 , C07K14/565 , C12N9/96 , A61K47/60 , C07K14/59 , C07K14/61 , C07K14/705 , A61K47/64
Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
-
Patent Agency Ranking
公开(公告)号：US20190225957A1
公开(公告)日：2019-07-25
申请号：US16228144
申请日：2018-12-20
Applicant: Bioverativ Therapeutics Inc.
Inventor： Joe SALAS , Elena KISTANOVA , Vu Phong HONG , Adam R. MEZO , Robert T. PETERS
Abstract: The invention provides chimeric clotting factors comprising an activatable clotting factor and an enhancer moiety. The activatable clotting factor allows the chimeric clotting factor to be activated at the site of coagulation. The enhancer moiety can additionally improve procoagulation activities of the chimeric clotting factors. The chimeric clotting factors can further be improved by fusion to a half-life extender, which improves a pharmacokinetics property of the chimeric clotting factor. The invention also includes methods of making and methods of using these chimeric clotting factors.
-
公开(公告)号：US20220135959A1
公开(公告)日：2022-05-05
申请号：US17496092
申请日：2021-10-07
Applicant: Bioverativ Therapeutics Inc.
Inventor： Joe SALAS , Elena KISTANOVA , Vu Phong HONG , Adam R. MEZO , Robert T. PETERS
Abstract: The invention provides chimeric clotting factors comprising an activatable clotting factor and an enhancer moiety. The activatable clotting factor allows the chimeric clotting factor to be activated at the site of coagulation. The enhancer moiety can additionally improve procoagulation activities of the chimeric clotting factors. The chimeric clotting factors can further be improved by fusion to a half-life extender, which improves a pharmacokinetics property of the chimeric clotting factor. The invention also includes methods of making and methods of using these chimeric clotting factors.
-
公开(公告)号：US20230023927A1
公开(公告)日：2023-01-26
申请号：US17830745
申请日：2022-06-02
Applicant: BIOVERATIV THERAPEUTICS INC.
Inventor： Robert T. PETERS , Adam R. MEZO , Daniel S. RIVERA , Alan J. BITONTI , Susan C. LOW
IPC: C07K14/755 , C07K14/555 , A61K47/64 , A61K47/68 , C07K14/59 , C07K14/475 , C07K16/00 , C12N9/64 , C07K14/565 , A61K47/60 , C07K14/505 , C07K14/705 , C07K14/745 , C12N9/96 , C07K14/61 , C07K14/56 , A61K38/00
Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
-
公开(公告)号：US20220243189A1
公开(公告)日：2022-08-04
申请号：US17577684
申请日：2022-01-18
Applicant: Bioverativ Therapeutics Inc.
Inventor： Vu Phong HONG , Adam R. MEZO , Joe SALAS , Robert PETERS
Abstract: The present disclosure provides protease-activatable procoagulant compounds comprising a procoagulant polypeptide, e.g., a procoagulant peptide and/or clotting factor, and a linker comprising a protease-cleavable substrate (e.g., a synthetic thrombin substrate) and a self-immolative spacer (e.g., p-amino benzyl carbamate). Upon cleavage of the protease-cleavable substrate by a protease (e.g., thrombin), the self-immolative spacer cleaves itself from the procoagulant polypeptide such that the polypeptide is in an underivatized and active form. Also provided are pharmaceutical compositions, methods for treating bleeding disorders using the disclosed compounds, methods of enhancing in vivo efficacy of procoagulant polypeptides, methods of increasing the efficacy of proteolytic cleavage of compounds comprising procoagulant polypeptides, methods of activating procoagulant polypeptides, and methods of releasing a procoagulant polypeptide from a heterologous moiety such as PEG.
-
公开(公告)号：US20190309280A1
公开(公告)日：2019-10-10
申请号：US16357153
申请日：2019-03-18
Applicant: Bioverativ Therapeutics Inc.
Inventor： Vu Phong HONG , Adam R. MEZO , Joe SALAS , Robert PETERS
Abstract: The present disclosure provides protease-activatable procoagulant compounds comprising a procoagulant polypeptide, e.g., a procoagulant peptide and/or clotting factor, and a linker comprising a protease-cleavable substrate (e.g., a synthetic thrombin substrate) and a self-immolative spacer (e.g., p-amino benzyl carbamate). Upon cleavage of the protease-cleavable substrate by a protease (e.g., thrombin), the self-immolative spacer cleaves itself from the procoagulant polypeptide such that the polypeptide is in an underivatized and active form. Also provided are pharmaceutical compositions, methods for treating bleeding disefficacy orders using the disclosed compounds, methods of enhancing in vivo of procoagulant polypeptides, methods of increasing the efficacy of proteolytic cleavage of compounds comprising procoagulant polypeptides, methods of activating procoagulant polypeptides, and methods of releasing a procoagulant polypeptide from a heterologous moiety such as PEG.
-
-
-
-
-
Search Results
6
records
(took 0.021 seconds)
